RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced that management will present at three upcoming virtual
investor conferences in September:
- The H.C. Wainwright 22nd Annual Global Investment
Conference on Monday, September 14, 2020, at 1:00 pm
E.T.
- The Cantor Fitzgerald Global Healthcare Conference
on Wednesday, September 16, 2020, at 11:20 am
E.T.
- The Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit on Tuesday, September 22,
2020, at 11:40 am E.T.
Each presentation will be webcast live and can be accessed by
visiting the Events and Webcasts section of the Company's
website: http://investors.proventionbio.com/events. Each
webcast will be archived on the Company's website for 90 days
following the presentation.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company leveraging a transformational drug development strategy
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to source, transform and develop
therapeutic candidates targeting the high morbidity, mortality and
escalating costs of autoimmune diseases. Provention's diversified
portfolio includes teplizumab, a clinical-stage candidate that has
been shown in a clinical study to delay the onset of
insulin-dependent type 1 diabetes (T1D) in at-risk patients during
the presymptomatic phase of the disease as compared to placebo. The
Company's portfolio includes additional clinical product
development candidates that have demonstrated in pre-clinical
or clinical studies proof-of-mechanism and/or proof-of-concept
in other autoimmune diseases, including celiac disease and
lupus.
Investor Contact:
Sam
Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-upcoming-virtual-investor-conferences-301124367.html
SOURCE Provention Bio, Inc.